SER 287

Drug Profile

SER 287

Alternative Names: SER-287

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seres Therapeutics
  • Class Anti-inflammatories; Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 04 Dec 2017 SER 287 receives Orphan Drug status for Ulcerative colitis (In adolescents, In children, In infants, In neonates) in USA
  • 09 Nov 2017 Updated adverse events and efficacy data from a phase Ib trial in Ulcerative colitis released by Seres Therapeutics
  • 13 Oct 2017 Seres Therapeutics completes a phase I trial for Ulcerative colitis (Second-line therapy or greater) in USA (PO) (NCT02618187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top